From the article:
"Whilst significant reductions in pain NRS and KOOS subscales were observed in this study, these were of similar magnitude to changes seen over similar periods in the placebo arm of recent placebo-controlled knee OA pharmacological RCTs. Moreover, it is not a randomised clinical trial (RCT) and there is no control group, the placebo response could be playing an important role in this open-label study."
In short, the oral formulation doesn't work.
- Forums
- ASX - By Stock
- PAR
- research reports and media
research reports and media, page-3584
-
- There are more pages in this discussion • 867 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PAR (ASX) to my watchlist
(20min delay)
|
|||||
Last
24.0¢ |
Change
0.015(6.67%) |
Mkt cap ! $83.98M |
Open | High | Low | Value | Volume |
22.5¢ | 24.0¢ | 22.5¢ | $173.6K | 743.6K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
8 | 99346 | 22.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
24.0¢ | 131244 | 5 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
8 | 99346 | 0.225 |
5 | 44676 | 0.220 |
7 | 82313 | 0.215 |
13 | 181424 | 0.210 |
8 | 128042 | 0.205 |
Price($) | Vol. | No. |
---|---|---|
0.240 | 131244 | 5 |
0.245 | 56918 | 2 |
0.250 | 89857 | 4 |
0.255 | 100000 | 1 |
0.260 | 1333 | 1 |
Last trade - 16.10pm 13/11/2024 (20 minute delay) ? |
Featured News
PAR (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Michael Thurn, CEO & MD
Michael Thurn
CEO & MD
SPONSORED BY The Market Online